SCHEMBL18758576

SCHEMBL18758576

CCc1ccc(CN2CCn3nc(C(F)(F)F)c(C(=O)N[C@@H](C)c4ccc(C(=O)OC)cc4)c32)cc1

nearest known ligand 0.43

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
▸ PTGER4 P35408 15/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ACACB O00763 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28622506 1.00 PTGER4 (0.43) PTGER4ALDH1A1LMNAACACB
SCHEMBL28630102 0.94 PTGER4 (0.49) PTGER4ALDH1A1LMNAACACB
SCHEMBL28627341 0.94 PTGER4 (0.49) PTGER4
SCHEMBL18758530 0.94 PTGER4 (0.46) PTGER4ACACB
SCHEMBL28922420 0.94 PTGER4 (0.43) PTGER4ACACB
SCHEMBL18758745 0.94 PTGER4 (0.49) PTGER4
SCHEMBL18758489 0.94 PTGER4 (0.43) PTGER4ACACB
SCHEMBL18758565 0.94 PTGER4 (0.43) PTGER4ACACB
SCHEMBL21081514 0.94 PTGER4 (0.49) PTGER4ALDH1A1LMNAACACB
SCHEMBL18758490 0.94 PTGER4 (0.43) PTGER4ACACB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11434246-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2022-09-06 — — US disclosed
US-20210347779-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-11-11 — — US disclosed
US-10941148-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2021-03-09 — — US disclosed
US-20190315754-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-10-17 — — US disclosed
US-10316040-B2 EP4 antagonists EISAI R&D MANAGEMENT CO., LTD. (JP) 2019-06-11 — — US disclosed
WO-2017066633-A1 EP4 ANTAGONISTS EISAI R&D MANAGEMENT CO., LTD. (JP) 2017-04-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11434246-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885ALDH1A1 956/4885LMNA 3809/4885
US-10316040-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885ALDH1A1 956/4885LMNA 3809/4885
US-10941148-B2 EP4 antagonists PTGER4, PTGER3, PTGER1 PTGER4 1/4885ALDH1A1 956/4885LMNA 3809/4885
US-20190315754-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 PTGER4 1/4885ALDH1A1 956/4885LMNA 3809/4885
US-20210347779-A1 EP4 ANTAGONISTS PTGER4, PTGER3, PTGER1 PTGER4 1/4885ALDH1A1 956/4885LMNA 3809/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback